Shattuck Labs (NASDAQ:STTK) Upgraded at Leerink Partnrs

Shattuck Labs (NASDAQ:STTK) was upgraded by equities researchers at Leerink Partnrs to a “strong-buy” rating in a research note issued on Monday,Zacks.com reports.

Separately, Leerink Partners assumed coverage on Shattuck Labs in a research report on Monday. They issued an “outperform” rating and a $4.00 price target on the stock. Four investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $7.50.

Shattuck Labs Trading Down 0.9 %

NASDAQ STTK opened at $1.16 on Monday. The business’s 50-day moving average price is $1.24 and its two-hundred day moving average price is $1.60. Shattuck Labs has a 12 month low of $0.94 and a 12 month high of $11.76. The firm has a market capitalization of $55.38 million, a PE ratio of -0.76 and a beta of 1.66.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in STTK. GSA Capital Partners LLP acquired a new position in shares of Shattuck Labs in the 3rd quarter valued at about $121,000. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Shattuck Labs by 44.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 178,228 shares of the company’s stock valued at $622,000 after purchasing an additional 54,505 shares during the period. FMR LLC lifted its stake in shares of Shattuck Labs by 0.4% in the 3rd quarter. FMR LLC now owns 7,159,090 shares of the company’s stock valued at $24,985,000 after purchasing an additional 26,460 shares during the period. MetLife Investment Management LLC raised its stake in Shattuck Labs by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 24,596 shares of the company’s stock worth $86,000 after buying an additional 13,859 shares during the period. Finally, Atom Investors LP acquired a new position in Shattuck Labs during the 3rd quarter worth approximately $35,000. 58.74% of the stock is owned by institutional investors and hedge funds.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.